(702) 683-8946

Monday - Friday 9am to 5pm



Buy and register domain names online from CRWE Domains. Web hosting, spam-free email, web marketing, secure SSL Certificates and more




Place Your Ad Here! Advertise your business online on CRWE WORLD. Your Company, product, or service in front of the world!

Contact Us: contact@crweworld.com




CRWE Info ( CRWE.Info ) provides news and updates about Crown Equity Holdings Inc. and the CRWE World platform




Submit Your Press Release/News to the CRWE WORLD Network for $14.95! Increase Visibility, Boost Your Business




Quest Diagnostics Inc. (NYSE:DGX) offers the most extensive clinical testing network in the U.S. The Company's extensive test menu includes routine biological testing; complex and specialized molecular and gene-based testing, and anatomic pathology testing. These services primarily help identify disease or risk factors for disease and predict and monitor response to treatment.


10 Result: Bristol-Myers Squibb

FDA approves Opdivo to treat advanced form of kidney cancer

November 23rd, 2015

November 23, 2015 - The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. “Opdiv. Read more

FDA expands approved use of Opdivo in advanced lung cancer

October 11th, 2015

Redistributed by CRWEPRESSRELEASE Opdivo demonstrates survival benefit in squamous and non-squamous non-small cell lung cancer Release Date: October 9, 2015 The U.S. Food and Drug Administration today approved Opdivo (nivolumab) to treat pat. Read more

Heat Biologics: Immunotherapy Vaccine to Transform Cancer Treatment

July 16th, 2015

NEW YORK, NY / CRWEPRESSRELEASE / July 16, 2015 / We all know that cancer affects many of our friends and family, but why don't we all get cancer? We now know that our immune system is continuously fighting and destroying potential cancer cells.Wh. Read more

Pluristem's PLX Cells Get Green Light for Fast Track Clinical Trials in Europe and Japan

June 02nd, 2015

NEW YORK, NY / CRWEPRESSRELEASE / June 2, 2015 / Quick commercialization of drugs in clinical trials has long been held as a fantasy for makers of pharmaceuticals and biologics. With recent news, it appears the fantasy may become reality, featuring P. Read more

CEL-SCI is a Rare Value Opportunity in Cancer Immunotherapy Stocks

April 23rd, 2015

NEW YORK, NY / CRWEPRESSRELEASE / April 23, 2015 / Cancer immunotherapy is scorching hot. At no time in medical history has a new cancer treatment been so widely researched and highly paid for. Over the last 50 years, the only medicine for cancer has. Read more

Cel-Sci's Cancer Immunotherapy In Phase III Is Value Opportunity

March 12th, 2015

BALTIMORE, MD / CRWEPRESSRELEASE / March 12, 2015 / Cancer immunotherapy has become today's word for treating patients with death-causing diseases, but progress and valuations within companies run a broad course. In this article, I will explain to in. Read more

Helius Medical Technologies Announces Appointment of Joyce LaViscount as New Director

March 03rd, 2015

NEWTOWN, PA / CRWEPRESSRELEASE / March 3, 2015 / Helius Medical Technologies, Inc. (CNSX:HSM; OTCMKTS:HSDT) ("HMT", "Helius" or the "Company"), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma. Read more

Pacific Therapeutics Announces First Nine Months 2014 Financial Results

December 02nd, 2014

VANCOUVER, BC / CRWEPRESSRELEASE / December 2, 2014 / Pacific Therapeutics Ltd. (CNSX:PT) (OTCMKTS:PCFTF) (1P3.F) (the "Company") has completed a phase 1 trial of its lead product for fibrosis, PTL-202, (a $4 billion market opportunity) with positive. Read more

CEO Comments on Diagnostic Breakthrough for Pulmonary Fibrosis

November 13th, 2014

VANCOUVER, BC, Canada /CRWE Press Release / November 13, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company") is a clinical stage specialty pharmaceutical company focused on the repurposing and reformulat. Read more

Pacific Therapeutics CEO Comments on Big Pharmas Recent Interest In Acquiring Therapies to treat Fibrosis

November 06th, 2014

VANCOUVER, BC, Canada /CRWE Press Release / November 6, 2014 / Pacific Therapeutics Ltd. (CSE: PT) (OTC Markets: PCFTF) (Frankfurt: 1P3) (the "Company") is a clinical stage specialty pharmaceutical company focused on the repurposing and r. Read more

Load More Content

News By Industries